Esta página ha sido traducida por una máquina. Otras páginas pueden seguir apareciendo en inglés. View in English

Una revisión exhaustiva de los últimos enfoques para el manejo de la hipercolesterolemia: un análisis comparativo de los tratamientos convencionales y nuevos: Parte II

  • 0Faculty of Pharmacy, "Victor Babeș" University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timișoara, Romania.

|

|

Resumen

Este resumen es generado por máquina.

Las nuevas terapias farmacológicas ofrecen nuevas esperanzas para controlar la hipercolesterolemia y reducir el riesgo de enfermedades cardiovasculares. Estos tratamientos avanzados se dirigen a vías específicas para pacientes con alto riesgo residual o intolerancia a las estatinas.

Área De La Ciencia

  • Cardiología
  • Farmacología
  • La genética

Sus Antecedentes

  • Las enfermedades cardiovasculares (ECV) son la principal causa de muerte en el mundo, con la hipercolesterolemia como un factor de riesgo modificado clave.
  • La revisión anterior cubrió el metabolismo de los lípidos, la aterosclerosis, las complicaciones, la evaluación del riesgo y las terapias convencionales (estatinas, ezetimiba).

Objetivo Del Estudio

  • Revisar las terapias farmacológicas emergentes para el tratamiento de la dislipidemia.
  • Para explorar nuevos agentes para pacientes con alto riesgo cardiovascular residual, hipercolesterolemia familiar o intolerancia a las estatinas.

Principales Métodos

  • Revisión de los mecanismos, las aplicaciones clínicas, la seguridad y la farmacogenética de los nuevos agentes.
  • Centrarse en los inhibidores de PCSK9, la terapia con siRNA, los inhibidores de la LCA, los inhibidores de la MTP y los inhibidores de ANGPTL3.

Principales Resultados

  • Los nuevos agentes como los inhibidores de PCSK9, el inclisiran, el ácido bempedoico, la lomitapida y el evinacumab proporcionan opciones de tratamiento dirigidas.
  • Estas terapias abordan las limitaciones de los tratamientos estándar, ofreciendo alternativas para grupos específicos de pacientes.

Conclusiones

  • Las terapias emergentes amplían el panorama de manejo de la dislipidemia, permitiendo una atención más individualizada al paciente.
  • Los avances en medicina de precisión son cruciales para optimizar las estrategias de tratamiento y mejorar los resultados cardiovasculares.

Videos de Conceptos Relacionados

Atherosclerosis III: Management 01:26

33

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents 01:20

865

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Cholesterol: Significance and Regulation 01:29

669

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

Coronary Artery Disease IV: Preventive Measures 01:26

32

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Hypertension IV: Drug Therapy and Lifestyle Modifications 01:28

37

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...

Angina IV: Management 01:26

22

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...